IL1B -511 polymorphism and association with susceptibility and prognosis in patients with papillary thyroid carcinoma

• Autor(a) principal: Silva, Izabel Cristina Rodrigues da
• Data de Publicação: 2023
• Outros Autores: Pessoa, Vinícius Guimarães, Bonasser, Larissa Sousa Silva, Souza, Jéssica Nayane Gomes de, Freitas, Renata de Souza, Silva, Calliandra Maria de Souza, Morais, Rafael Martins de, Oliveira, Jamila Reis de
• Tipo de documento: Artigo
• Idioma: por; eng
• Título da fonte: REVISA : Revista de Divulgação Científica Sena Aires (Online)
• Texto Completo: https://rdcsa.emnuvens.com.br/revista/article/view/212
• topic: Câncer de tireoide; Radioisótopos do iodo; Interleucina-1 beta; Polimorfismo genético.; Thyroid cancer; Iodine radioisotopes; Interleukin-1 beta; Genetic polymorphism

Objective: To associate the presence of SNP IL1B -511 (rs16944) with susceptibility to TLC, as well as to compare serum cytokine levels before and seven days after iodotherapy, along with other clinical characteristics of patients. Method: This is a case-control study, in which blood samples were obtained from 52 individuals (26 in each group). Genotyping was performed using the PCR-RFLP strategy. Serum IL-1β levels were measured using an enzyme immunoassay kit (ELISA). Tests for means and association studies were performed considering a significance level of 5%. Results: There was no statistical difference regarding genotypic distribution between case and control individuals, and these groups did not differ in relation to cytokine dosages. However, cytokine levels increased significantly after iodine therapy, and patients with the CC genotype showed higher protein production, but this increase was not correlated with the administered radiopharmaceutical dose. Conclusion: IL1B-511 polymorphism was not associated with susceptibility to TLC, but serum cytokine levels increased with the treatment of iodotherapy, and this elevation was genotype dependent